戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 rge), and 3 months after post-test (6 months after discharge).
2 scharge) and late readmissions (8 to 30 days after discharge).
3 (defined as the hospitalization plus 90 days after discharge).
4          Children were followed for 26 weeks after discharge.
5  CI 4.0-6.8]), a mean of 1 year of follow-up after discharge.
6 ported to be low, adverse outcomes can occur after discharge.
7 .73 m2 for at least 3 months during the year after discharge.
8 ation, and 11% (n=174) were impaired 1 month after discharge.
9 tus of ICU survivors was assess until 1 year after discharge.
10 y, during hospitalization, and up to 2 weeks after discharge.
11 nt death and death during follow-up over 1 y after discharge.
12  expected they could manage themselves alone after discharge.
13 icant in landmark analyses beginning 30 days after discharge.
14 isk of readmission and death within 6 months after discharge.
15 spiratory or neurosensory morbidity or death after discharge.
16 e hospital and 1405 infants were followed up after discharge.
17 rction, bleeding, and recurrent renal injury after discharge.
18 neurosensory impairment, and 12 infants died after discharge.
19 eductions in hospital 30-day mortality rates after discharge.
20 6% of patients over an average of 3.5 months after discharge.
21         There were no vascular complications after discharge.
22  colectomy consume similar amounts of opioid after discharge.
23 ization for GI bleed and received octreotide after discharge.
24 ilitation and outpatient cardiologist visits after discharge.
25 received oral versus intravenous antibiotics after discharge.
26  rates of suicide remain high for many years after discharge.
27  high mortality rate within the first months after discharge.
28 ing their hospitalization and up to 2 months after discharge.
29 ries had higher rates of long-term mortality after discharge.
30  2013 and analyzed readmissions over 30 days after discharge.
31 s new, persistent opioid use during the year after discharge.
32 al research studies evaluating ARF survivors after discharge.
33 l outcomes occurring after the first 30 days after discharge.
34 on rates and hospital 30-day mortality rates after discharge.
35  with 46.3% occurring between days 30 and 90 after discharge.
36 h from the time of randomization to 6 months after discharge.
37 od culture, and wound culture) in the 7 days after discharge.
38 patients returned from Ziv Hospital to Syria after discharge.
39 and/or hospitalization during the first year after discharge.
40 atient or observation status) within 30 days after discharge.
41 ed with postoperative readmissions and death after discharge.
42  and 1,185 (4.6%) died between 8 and 30 days after discharge.
43  diagnoses for 30-day and 7-day readmissions after discharge.
44 L) improvement (>/=1 log10 decline) 6 months after discharge.
45 d, followed by 5 phone calls in the 10 weeks after discharge.
46 pital discharge and at 3 months and 6 months after discharge.
47 MI hospitalization, 32.6% became nonadherent after discharge.
48 rogression to end-stage renal disease (ESRD) after discharge.
49 e readmission and mortality within 8-30 days after discharge.
50 diate-/long-term acute care facility 30 days after discharge.
51 discharge, which persisted for up to 5 years after discharge.
52 patient visit with a clinician within 7 days after discharge.
53 ort on patient admission to the hospital and after discharge.
54  was not significantly associated with death after discharge.
55 ased risk of mortality diminished at 2 years after discharge.
56 tality from infections while in hospital and after discharge.
57 e AMI hospitalization, 37.7% became adherent after discharge.
58 jor bleeding in acutely ill medical patients after discharge.
59 dmitted with first-time MI and alive 30 days after discharge.
60 after ingestion of egg approximately one day after discharge.
61 <7 d and >/=7 d) and readmission within 30 d after discharge.
62 admission timing was determined from the day after discharge.
63  payments during hospitalization and 30 days after discharge.
64 t the time of the procedure, and 24-72 hours after discharge.
65 ing hospitalization or to prevent recurrence after discharge.
66 lization is associated with statin intensity after discharge.
67 intensive care) wards and again three months after discharge.
68 ce that persisted throughout the entire year after discharge.
69 ion, and 41.5% of the UC-VTEs were diagnosed after discharge.
70 on were significantly less likely to go home after discharge.
71 7 and 14 during treatment as well as 8 weeks after discharge.
72 ommendation to use counseling and medication after discharge.
73 offered patients coordinated continuing care after discharge.
74 ences had largely resolved by 9 to 12 months after discharge.
75 tered as 3-day courses at 2, 6, and 10 weeks after discharge.
76 ts at 3 months and 382 patients at 12 months after discharge.
77 ns are effective only if treatment continues after discharge.
78 dures reported counts of unused opioid pills after discharge.
79  >50% had persistent hepatitis up to 1 month after discharge.
80 pture all hospital encounters that may occur after discharge.
81                       She has had no symptom after discharge.
82 ospitalization and died a median of 169 days after discharge.
83 ome was hospital readmission within 180 days after discharge.
84 ed with morbidity that can persist for years after discharge.
85  of inpatient use and risk for long-term use after discharge.
86 : 342 (3.1%) during treatment and 637 (5.8%) after discharge.
87 l healthcare payments over the first 30 days after discharge.
88        All subjects were followed for 1 year after discharge.
89 aureus (MRSA) are at high risk for infection after discharge.
90 ode from the index admission through 30 days after discharge.
91 o discharge and at 30, 90, 180, and 365 days after discharge.
92 ies that generally affected readmission risk after discharge.
93 s or affected mortality in the 30-day period after discharge.
94 highest risk of respiratory hospitalizations after discharge.
95 replacement therapy) evaluated up to 90 days after discharge.
96 sociated adverse events reported by patients after discharge.
97  and/or prescription orders) 90 and 365 days after discharge.
98 ng 1.65 (95% CI 1.02-2.67) in the fifth year after discharge.
99 iations were similar for opioid use 365 days after discharge.
100 arental report of breathing problem episodes after discharge.
101 nd total cost of care over the first 30 days after discharge.
102 .2% among acquirers occurred within 180 days after discharge.
103 r readmissions and lower healthcare payments after discharge.
104 rom death to resumption of normal activities after discharge.
105 The suicide rate was highest within 3 months after discharge (1132; 95% CI, 874-1467) and among patie
106 ity risks to decline 50% from maximum values after discharge, (2) time required for the adjusted read
107 ted continuous abstinence rates for 6 months after discharge (27% vs 16% for standard care; RR, 1.70
108 d rehospitalization for respiratory problems after discharge (28.3% vs 51.1%; P = .03); 39.5% vs 50%
109 7; 95% CI, 0.17-0.81; p = 0.005) and 90 days after discharge (37.8% vs. 70.6%; relative risk = 0.47;
110 , nearly half (49.1%) had antibiotic overuse after discharge (56.9% pneumonia; 38.7% UTI).
111  scores in the PACU; 4 [3-7] for pain scores after discharge; 6.7 [3.3-10] for opioid use after disch
112 diogenic shock patients in the first 60 days after discharge (adjusted HR: 1.62; 95% confidence inter
113  at shorter intervals of 6 months and 1 year after discharge also showed no significant difference be
114 xcluding 916 patients who progressed to ESRD after discharge, although it was significantly amplified
115                      At 6 months and 2 years after discharge among beneficiaries 66 to 75 years of ag
116 ve metric to characterize antibiotic overuse after discharge among hospitalized patients treated for
117 d emergency department visits within 30 days after discharge among patients undergoing a variety of s
118 d with BP elevation during the first 2 years after discharge among previously normotensive adults.
119 sociated with receiving an ICD within 1 year after discharge and 2-year mortality associated with ICD
120 ed Part D data to calculate beta-blocker use after discharge and beta-blocker use over time.
121  readmission risk was highest on days 2 to 4 after discharge and declined thereafter, and women were
122 rtional over time, being highest immediately after discharge and decreasing thereafter.
123 pital stay were less likely to be readmitted after discharge and had lower total healthcare spending.
124 o be unrelated to the interventions (seizure after discharge and intracerebral haemorrhage in the rec
125 to vital statistics data to obtain mortality after discharge and matched to New York's administrative
126 filling an opioid prescription 3 to 6 months after discharge and recorded clinically recognized opioi
127 ion was largely driven by readmissions early after discharge and was not significant in landmark anal
128 dicaid coverage and more cardiologist visits after discharge and who participated in cardiac rehabili
129 ures, mortality, and the rate of readmission after discharge) and data on hospital mergers and acquis
130  they affect early readmissions (0 to 7 days after discharge) and late readmissions (8 to 30 days aft
131 s within 30 days and between 31 and 180 days after discharge) and viral load (VL) improvement (>/=1 l
132 e collected at baseline, post-test (3 months after discharge), and 3 months after post-test (6 months
133 ntation, twice monthly in the first 3 months after discharge, and at each follow-up visit until month
134 rams to target vulnerabilities predischarge, after discharge, and during re-presentation to the emerg
135                 Patients were contacted 3 mo after discharge, and electronic records were accessed to
136 .6%) fluoroquinolone treatment days occurred after discharge, and hospitals with fluoroquinolone stew
137 ncy liaison, intensive follow-up immediately after discharge, and longer-term social support are indi
138  arrangements made for MOUDs to be continued after discharge, and MOUDs should not be discontinued be
139 ferred to a hospital, 1 patient died 2 weeks after discharge, and no health care workers became infec
140  of hospital stay, no readmission <= 90 days after discharge, and no postoperative mortality <= 90 da
141  filled an opioid prescription 3 to 6 months after discharge, and this persistent use was associated
142  of death between the first day and 10 years after discharge, and to compare risks between adversity-
143 ician follow-up appointment less than 1 week after discharge, and, for high-risk patients, structured
144 of spontaneous activity, mechanically evoked after-discharges, and/or increased responses to mechanic
145 after discharge; 6.7 [3.3-10] for opioid use after discharge; and 6 of 23 [26.1%] for incidence of na
146 I, 0.67 to 0.82]; P < .001) to 61 to 90 days after discharge (ARD, -11.1% [95% CI, -13.2% to -8.4%];
147 g patient factors associated with opioid use after discharge are lacking.
148  however, data examining rates of thrombosis after discharge are limited.
149 had twice as many new fluoroquinolone starts after discharge as hospitals without (15.6% vs 8.4%; P =
150 as predictor and respiratory hospitalization after discharge as outcome.
151  and survival was 17.7% with median survival after discharge being 20.6 months.
152         Clinicians may help protect patients after discharge by serving as a liaison between primary
153                                    Two weeks after discharge, children were randomly assigned to rece
154      The IV iron group had higher Hb 4 weeks after discharge compared with the usual care group (1.9
155                        However, at 12 months after discharge, compared with white men, black and Hisp
156 he 9136 patients surviving the first 30 days after discharge constituted the study population.
157 a 30% decline in eGFR at 30, 60, and 90 days after discharge demonstrated adjusted hazard ratios (95%
158 ts got readmitted to hospital within 30 days after discharge due to various reasons.
159 ssion, and quality of life at 1 and 6 months after discharge (EQ-5D-5L [EuroQol Group, 5-level] quest
160  2016); patients were followed up for 1 year after discharge (final date of follow-up was October 23,
161  for an anticoagulant was filled immediately after discharge for 77 (1.5%) patients, and a low-molecu
162 risk of rehospitalization in the first month after discharge for acute myocardial infarction (AMI).
163 le Angina Questionnaire administered 30 days after discharge for acute myocardial infarction, wherein
164 across conditions, women are at highest risk after discharge for acute myocardial infarction.
165 cords and was examined at 90 days and 1 year after discharge for beta-blockers, platelet P2Y12 recept
166 thly trends in 30-day RARRs and 30-day RAMRs after discharge for each condition.
167 improving the overall health of older adults after discharge for hip fracture.
168                 Home health care and PAC use after discharge for hospitalized children is infrequent,
169  0.90; 95% CI, 0.83 to 0.97) and were higher after discharge from a for-profit hospital (IRR, 1.33; 9
170 ch to predict all-cause readmissions 30 days after discharge from a heart failure hospitalization and
171     In-person clinic follow-up within 7 days after discharge from a heart failure hospitalization is
172 for predicting 30 days all-cause readmission after discharge from a HF admission, and (2) to examine
173 spitalization rates were significantly lower after discharge from a hospital that had an outpatient p
174 daily risk of rehospitalization/death 1 year after discharge from a population of Medicare fee-for-se
175                       Unplanned readmissions after discharge from acute care for traumatic injury are
176  emergency department, or die within 30 days after discharge from an acute hospitalization, we conduc
177 ors of EVD in Sierra Leone, at various times after discharge from an Ebola treatment unit (ETU), in t
178                The frequency of early stroke after discharge from an emergency department with a diag
179 tween days 8 and 30, follow-up within a week after discharge from an emergency department with atrial
180  with anaphylaxis to undergo allergy testing after discharge from an emergency department.
181 survivors were defined as those who survived after discharge from first hospitalization with a diagno
182                               High mortality after discharge from hospital following acute illness ha
183     A regular screening of post-ICU patients after discharge from hospital should be an integral part
184 fast-track surgery, they often come to light after discharge from hospital.
185  healthcare providers and ancillary services after discharge from hospital.
186 inistered orally and were given for 3 months after discharge from hospital.
187 tion, and were able to access rehabilitation after discharge from hospital.
188 igh responsiveness (16-31 point improvements after discharge from hospitalization; standardized respo
189 nt of septic and nonseptic patients 6 months after discharge from ICU.
190  of recurrent biliary events in the 365 days after discharge from index admission.
191 hen 20 mg daily until the earliest of 3 days after discharge from intensive care, study day 28, or de
192 y help patients and families face challenges after discharge from intensive care.
193  infant gut microbiota and resistome persist after discharge from neonatal intensive care units.
194             To quantify the rates of suicide after discharge from psychiatric facilities and examine
195                             The suicide rate after discharge from psychiatric facilities was the main
196 30 days on surveys taken 4, 8, and 12 months after discharge from residential treatment.
197        We hypothesized that photodegradation after discharge from the dark sedimentary environment re
198 ior (47.8%) and occurred within the 2 months after discharge from the Ebola treatment center.
199 ut of 6 survivors presented ocular disorders after discharge from the Ebola treatment center.
200 stantial proportion of MRSA infections occur after discharge from the hospital.
201  for Ebola virus disease (EVD) 1 or 3 months after discharge from the hospital.
202              Patients were followed 6 months after discharge from the ICU for length of hospital stay
203 nization performance score measured 3 months after discharge from the ICU was used as a measure of fu
204  an unexpected susceptibility to cancer long after discharge from the ICU.
205  defined as any procedure related to the EVR after discharge from the index hospitalization.
206 ent is significantly increased in the months after discharge from the intensive care unit.
207                               Use of opioids after discharge from the postanesthesia care unit.
208 012 to incorporate inpatient BB continuation after discharge from the postanesthesia care unit.
209  tested positive for Ebola virus at 114 days after discharge from the treatment unit; specimens taken
210        Safe sex practices should be observed after discharge from treatment centers.
211 treatment, and short-term follow-up (2 weeks after discharge) from chart review and interviews with p
212 r, patients with follow-up more than 6 weeks after discharge had lower adherence at both 90 days (56.
213  exist on whether the use of early follow-up after discharge has improved over time.
214 on had a greater risk of all-cause mortality after discharge (hazard ratio, 1.38; 95% CI, 1.34-1.46).
215  to PAC facilities was 36% compared with 51% after discharge home.
216 rienced recurrent or sustained desaturations after discharge home.
217                                     One year after discharge, ICU survivors received a survey contain
218                                   Six months after discharge, improvement in muscle function enabled
219 er pediatric ICU discharge and HRQL 6 months after discharge in 2-week- to 17-year-olds mechanically
220 re discharge in 48.8% and a median of 2 days after discharge in 51.2%.
221 llow-up clinic visit occurred 1 week or less after discharge in 5542 (26.4%) patients, 1 to 2 weeks i
222 rse event (death) which occurred immediately after discharge in a patient with severe, end stage dise
223  antibiotics, use of intravenous antibiotics after discharge in children with complicated appendiciti
224 level association between antibiotic overuse after discharge in patients treated for pneumonia vs. UT
225 ed increased evoked activity and a prolonged after-discharge in spinal wide dynamic response (WDR) ne
226 harges to mechanical stimuli and exaggerated after-discharges in rats with bortezomib CIPN.
227 38.3% of severe hypocalcemic events occurred after discharge; in this subset, 59.1% experienced sever
228                                        Costs after discharge included those attributable to hospital
229 ring discharge and oxidation of this seepage after discharge into a pond where Fe-(oxyhydr)oxide prec
230 ulative mortality rate among NCTPs at 1 year after discharge is significant, particularly in the pres
231 whether this impairment resolves or persists after discharge is unknown.
232       Whether this survival benefit persists after discharge is unknown.
233 HHC) and facility-based postacute care (PAC) after discharge is well documented for adults, to our kn
234 spitalizations (readmissions to the hospital after discharge) is unknown.
235 servational study and followed up for 1 year after discharge (mean [SD] age, 33.9 [16.3] years; 79% w
236 1 [0-5] and 3.5 [0-6.8], respectively), pain after discharge (median [IQR], 3 [2-5] and 3 [1-5.5], re
237 -5] and 3 [1-5.5], respectively), opiate use after discharge (median [IQR], 6.7 [5-10] and 6.7 [3.3-1
238 ol group consumed significantly more opioids after discharge(median 121.3MME vs 23.5MME, P < 0.001).
239 9% were readmitted during the first 3 months after discharge (no significant differences compared wit
240 GFR decline of >/=30% at 30, 60, and 90 days after discharge occurred in 3.1%, 2.5%, and 2.6%, of sur
241                                        Death after discharge occurred in 69 patients (1.4%).
242 s the strongest factor associated with death after discharge (odds ratio, 6.7; 95% CI, 2.4-19.3).
243 inistered dose, and a prolonged surveillance after discharge of 48 h.
244 ailed treatment, with a median time to death after discharge of 9.9 months (IQR 4.2-17.4).
245 ss spectrometry enables analysis of a casing after discharge of a firearm revealing organic signature
246  as neuropsychologically impaired 3-6 months after discharge; of these, 23 provided 12-month follow-u
247 The impact of spontaneous bleeding occurring after discharge on long-term mortality is unknown.
248                                   Six months after discharge, only 5% of those not recognized as havi
249                         By the end of 1 year after discharge, only one third of all AMI survivors fil
250 ral edema, orthopnea) contribute to outcomes after discharge or how well decongestion is maintained.
251 30 days, in-hospital mortality and mortality after discharge (p < 0.05) (secondary endpoints).
252 interval, 0.87-0.94), 28 more home-time days after discharge (P<0.001), and lower all-cause mortality
253                                              After discharge, parents recorded all analgesics they ga
254                               Within 2 weeks after discharge, participants were queried on 5 domains:
255 , and utilization of intravenous antibiotics after discharge ranged from 0% to 91.7% across hospitals
256 has long-term effect on each adverse outcome after discharge, rather than the effect simultaneously.
257 ock, and cardiology follow-up within 2 weeks after discharge relative to patients who did not receive
258 ty in PB neurons, and a dramatic increase in after-discharges, responses that far outlast the stimulu
259 iflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total
260 Respiratory Questionnaire (SGRQ) at 6 months after discharge (score, 0 [best] to 100 [worst]; 4-point
261 s or behaviors and those in the first months after discharge should be a particular focus of concern.
262 MR, as well as XRD data on lithiated sample (after discharge) show that the material is associated wi
263 onary event recurrence within the first year after discharge than patients without FH despite the wid
264 d more deaths or readmissions for any reason after discharge than placebo.
265                                              After discharge, the analytical platform derived a perso
266                                              After discharge, the half-strength apple juice/preferred
267                                              After discharge, the primary end point occurred in 8.6%
268 al alone, and in-hospital plus up to 30 days after discharge), time to hospital discharge, and hospit
269 low-up of survivors should begin immediately after discharge to address sequelae as they arise and re
270 120) included transition support for 30 days after discharge to ensure adherence to discharge plan an
271                   Five-year overall survival after discharge to PAC facilities was 36% compared with
272               Antibiotics are often employed after discharge to prevent treatment failure in children
273 dication at discharge, and no patient called after discharge to request analgesic medications.
274 es across hospitals in hospital 30-day RAMRs after discharge varied by condition: HF, 0.008% (95% CI,
275                             The median delay after discharge was 350 days (IQR 223-491).
276                          Mortality at 1 year after discharge was also highest for patients with an el
277 sician-adjudicated events over the 12 months after discharge was assessed with the kappa statistic.
278                           Antibiotic overuse after discharge was associated between conditions, sugge
279                   Early outpatient follow-up after discharge was associated with a small increase in
280                           Antibiotic overuse after discharge was common and varied widely between hos
281 gh-intensity statins at 6 months and 2 years after discharge was defined by a proportion of days cove
282 isk of premature death during the first year after discharge was markedly higher than the risk of dea
283  [17 of 20] before surgery vs 83% [16 of 20] after discharge) was higher than survey adherence (65% t
284                                              After discharge, we established a new follow-up clinic w
285  mean hospital 30-day RARRs and 30-day RAMRs after discharge were 24.6% and 8.4% for HF, 19.3% and 7.
286 30-day risk-adjusted mortality rates (RAMRs) after discharge were calculated for each condition in ea
287                  Delusional memories 28 days after discharge were common (70%) yet unrelated to delir
288         For pneumonia, 63.1% of overuse days after discharge were due to excess duration; for UTI, 43
289 ach hospital's 30-day RARRs and 30-day RAMRs after discharge were examined for each condition.
290 out morbidity and readmission within 30 days after discharge were gathered from medical records.
291                           MACE that occurred after discharge were independently assessed by cardiolog
292 ve mortality rates at 1, 3, 6, and 12 months after discharge were investigated using the Social Secur
293  Death alone and major adverse kidney events after discharge were most common in the pneumonia + acut
294  Changes in HRQL before discharge and 1 week after discharge were similar (P > .05 for all comparison
295 hly changes in 30-day RARRs and 30-day RAMRs after discharge were weakly positive: HF, 0.066 (95% CI,
296 o be on optimal therapy by the end of 1 year after discharge, which is driven by a sex disparity in t
297 ajor adverse cardiovascular events at 1 year after discharge, which persisted for up to 5 years after
298  patient was readmitted to hospital 9 months after discharge with symptoms of acute meningitis, and w
299  (4.8%) had bleeding-related hospitalization after discharge, with the highest incidence of bleeding-
300                                              After discharge, women developed heart failure after STE

 
Page Top